about
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyProlongation of ERP latency and reaction time (RT) in simultaneous EEG/fMRI data acquisition.Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design.The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia.Recent advances in the treatment of delusional disorder.A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.The CATIE schizophrenia trial: results, impact, controversy.Review of antipsychotic medication administration: a proposal of intermittent dosing.Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosisVerbal and visual-spatial memory impairment in youth at familial risk for schizophrenia or affective psychosis: a pilot studyGenetics of the schizophrenias: a model accounting for their persistence and myriad phenotypes.Quantitative assessment of the frequency of normal associations in the utterances of schizophrenia patients and healthy controls.Prevalence of neurological soft signs and their neuropsychological correlates in typically developing Chinese children and Chinese children with ADHD.Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.Neuropsychiatric complications of HIV infection: public policy implications.Paul E. Meehl's influence on experimental psychopathology: fruits of the nexus of schizotypy and schizophrenia, neurology, and methodology.Baseline neurocognitive deficits in the CATIE schizophrenia trial.Neurological soft signs in individuals with schizotypal personality features.Earlier age of first diagnosis in schizophrenia is related to impaired motor control.Schizotypy and individual differences in the frequency of normal associations in verbal utterances.High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
P50
Q27320151-2AB8C07E-E8A4-492D-9E4A-87550A311C50Q31095654-89734054-C192-49F6-BAFD-EE435734B657Q33521197-BF426A42-2097-4C63-BAB1-64C7A56C6C3FQ34343579-1FEF8DAB-BEC8-4DE0-B2D9-C338AE1206B2Q34571116-84DFE0A0-96D8-4408-8EC9-86E28DA93EFBQ34579324-53834249-D936-4123-A4B3-72F3B0E55110Q34699698-93091495-A16A-4895-BEB3-1D8CAB2F809BQ35106343-1F896F30-AFF9-4053-B4CE-1AD45DA52C2BQ35115704-87C4CBAB-EBCC-4FFB-976F-27FCCABD27E4Q36154276-91175625-82C5-43DA-B001-3BDCA4A41C73Q36609585-39F9CBF3-63C2-4BA1-B26A-97A6B3C1F11EQ38020249-71A5DC08-BBB4-40F2-9236-77E9E51B577AQ38413984-E0272226-291F-4F4C-987F-3778A8A5907BQ43663609-364E0E61-ACD1-4097-ACD7-EDB82FC5B57CQ44096389-97E38F5D-A019-4CD2-9953-F188D1822752Q45063938-7D8F733B-515B-4AA5-ACE9-4BAE5FBA5DA1Q46176382-88C991A9-E43C-4DE7-9D0F-D783004BA5F4Q48125187-926BD297-8045-4BE6-BECB-07C8F5AFFBBDQ48622727-4B976D6A-5978-442F-927D-C3F874304B91Q50732363-B65B0CA8-737D-4634-8769-66CCC5726FCDQ51839649-391C084B-B05A-48B6-AB31-8153C08BDDDDQ51938817-8130EF36-7C7A-4EB8-A181-E294A6CE8D9CQ51980945-A6277A69-0001-4D45-B214-59BD8A47666EQ55057239-B60D38D0-DC1D-458D-9F55-C25B062CFF08
P50
name
Theo C Manschreck
@en
Theo C Manschreck
@nl
type
label
Theo C Manschreck
@en
Theo C Manschreck
@nl
prefLabel
Theo C Manschreck
@en
Theo C Manschreck
@nl